These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34870192)

  • 21. The prevalence of trimetazidine use in athletes in Poland: excretion study after oral drug administration.
    Jarek A; Wójtowicz M; Kwiatkowska D; Kita M; Turek-Lepa E; Chajewska K; Lewandowska-Pachecka S; Pokrywka A
    Drug Test Anal; 2014; 6(11-12):1191-6. PubMed ID: 25421604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possibility of analytical finding of glycerol caused by self-catheterization in doping control.
    Okano M; Nishitani Y; Kageyama S
    Drug Test Anal; 2014; 6(11-12):1151-4. PubMed ID: 25079056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacists as a Source of Advice on Medication Use for Athletes.
    Yee KC; De Marco M; Salahudeen MS; Peterson GM; Thomas J; Naunton M; Kosari S
    Pharmacy (Basel); 2020 Jan; 8(1):. PubMed ID: 31952349
    [No Abstract]   [Full Text] [Related]  

  • 24. Athletes' knowledge and views on OTC medication.
    Mottram D; Chester N; Atkinson G; Goode D
    Int J Sports Med; 2008 Oct; 29(10):851-5. PubMed ID: 18401811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary Supplement and Food Contaminations and Their Implications for Doping Controls.
    Walpurgis K; Thomas A; Geyer H; Mareck U; Thevis M
    Foods; 2020 Jul; 9(8):. PubMed ID: 32727139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
    Orr R; Grassmayr M; Macniven R; Grunseit A; Halaki M; Bauman A
    Int J Drug Policy; 2018 Jun; 56():40-45. PubMed ID: 29550541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intended or Unintended Doping? A Review of the Presence of Doping Substances in Dietary Supplements Used in Sports.
    Martínez-Sanz JM; Sospedra I; Ortiz CM; Baladía E; Gil-Izquierdo A; Ortiz-Moncada R
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 28976928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Banned substances and their incidence: A retrospective view of the national laboratory of prevention and doping control of Mexico.
    Mercado Soberanes K; Camacho Frías E; Rodríguez Balandrán L; Rodríguez Fermán ME; Mendoza Méndez N; Velasco-Bejarano B
    Adicciones; 2019 Jul; 31(3):201-211. PubMed ID: 30059594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. hGH isoform differential immunoassays applied to blood samples from athletes: decision limits for anti-doping testing.
    Hanley JA; Saarela O; Stephens DA; Thalabard JC
    Growth Horm IGF Res; 2014 Oct; 24(5):205-15. PubMed ID: 24973245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
    Gosetti F; Mazzucco E; Gennaro MC; Marengo E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doping Prevalence in Competitive Sport: Evidence Synthesis with "Best Practice" Recommendations and Reporting Guidelines from the WADA Working Group on Doping Prevalence.
    Gleaves J; Petróczi A; Folkerts D; de Hon O; Macedo E; Saugy M; Cruyff M
    Sports Med; 2021 Sep; 51(9):1909-1934. PubMed ID: 33900578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ensuring high quality in anti-doping laboratories.
    Boghosian T; Barroso O; Ivanova V; Rabin O
    Bioanalysis; 2012 Jul; 4(13):1591-601. PubMed ID: 22831475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Instructional design and assessment of an elective course on the use of drugs in sport.
    Awaisu A; Khalifa S; Mottram D; Ahmed A; Stuart M
    Curr Pharm Teach Learn; 2018 Aug; 10(8):1124-1131. PubMed ID: 30314549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance-Enhancing Drugs I: Understanding the Basics of Testing for Banned Substances.
    Cadwallader AB; Murray B
    Int J Sport Nutr Exerc Metab; 2015 Aug; 25(4):396-404. PubMed ID: 25675030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure and Development of the List of Prohibited Substances and Methods.
    Kinahan A; Budgett R; Mazzoni I
    Med Sport Sci; 2017; 62():39-54. PubMed ID: 28571027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence, knowledge and attitude of prohibited substances use (doping) among Saudi sport players.
    Al Ghobain M; Konbaz MS; Almassad A; Alsultan A; Al Shubaili M; AlShabanh O
    Subst Abuse Treat Prev Policy; 2016 Apr; 11():14. PubMed ID: 27083557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sport, Society, and Anti-Doping Policy: An Ethical Overview.
    Bloodworth AJ; McNamee M
    Med Sport Sci; 2017; 62():177-185. PubMed ID: 28571026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Veterinary medicines and competition animals: the question of medication versus doping control.
    Toutain PL
    Handb Exp Pharmacol; 2010; (199):315-39. PubMed ID: 20204593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.